Bernard, Olivier A.

Mutation in TET2 in Myeloid Cancers

Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine

Acute Myeloid Leukemia ResearchMyeloproliferative Neoplasms: Diagnosis and Treatment

Cited by 1,776

TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis

Quivoron, C., Couronné, L., Della Valle, V., Lopez, C. K., Plo, I., Wagner-Ballon, O., Do Cruzeiro, M., Delhommeau, F., Arnulf, B., Stern, M.-H., et al. (2011) · Cancer Cell

Acute Myeloid Leukemia ResearchChromatin Remodeling and Cancer

Cited by 924

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations

Yen, K., Travins, J., Wang, F., David, M. D., Artin, E., Straley, K., Padyana, A., Gross, S., DeLaBarre, B., Tobin, E., et al. (2017) · Cancer Discovery

Acute Myeloid Leukemia ResearchGlioma Diagnosis and Treatment

Cited by 471

Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis

Rasmussen, K. D., Jia, G., Johansen, J. V., Pedersen, M. T., Rapin, N., Bagger, F. O., Porse, B. T., Bernard, O. A., Christensen, J., & Helin, K. (2015) · Genes & Development

Acute Myeloid Leukemia ResearchEpigenetics and DNA Methylation

Cited by 270

A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL–PDGFRβ oncoprotein

Jousset, C., Carron, C., Boureux, A., Quang, C. T., Oury, C., Dusanter‐Fourt, I., Charon, M., Levin, J., Bernard, O., & Ghysdael, J. (1997) · The EMBO Journal

Genomics and Chromatin DynamicsRetinoids in leukemia and cellular processes

Cited by 207

TEL Is a Sequence-specific Transcriptional Repressor

Lopez, R. G., Carron, C., Oury, C., Gardellin, P., Bernard, O., & Ghysdael, J. (1999) · Journal of Biological Chemistry

Genomics and Chromatin DynamicsChromatin Remodeling and Cancer

Cited by 174

The TEL gene products: nuclear phosphoproteins with DNA binding properties

Poirel, H., Oury, C., Carron, C., Duprez, E., Laabi, Y., Tsapis, A., Romana, S. P., Mauchauffe, M., Le Coniat, M., Berger, R., et al. (1997) · Oncogene

Acute Lymphoblastic Leukemia researchGenomics and Chromatin Dynamics

Cited by 106

MAL/SRF complex is involved in platelet formation and megakaryocyte migration by regulating MYL9 (MLC2) and MMP9

Gilles, L., Bluteau, D., Boukour, S., Chang, Y., Zhang, Y., Robert, T., Dessen, P., Debili, N., Bernard, O. A., Vainchenker, W., et al. (2009) · Blood

Platelet Disorders and TreatmentsAcute Myeloid Leukemia Research

Cited by 80

A recurrent activating missense mutation in waldenstrom macroglobulinemia affects the DNA binding of the ETS transcription factor SPI1 and enhances proliferation

Roos-Weil, D., Decaudin, C., Armand, M., Della-Valle, V., Diop, M. K., Ghamlouch, H., Ropars, V., Hérate, C., Lara, D., Durot, E., et al. (2019) · Cancer Discovery

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 38

AG-221, an oral, selective, first-in-class, potent IDH2-R140Q mutant inhibitor, induces differentiation in a xenotransplant model

Quivoron, C., David, M., Straley, K., Travins, J., Kim, H., Chen, Y., Zhu, D., Saada, V., Bawa, O., Opolon, P., et al. (2014) · Blood

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 19